TVD Banner  

Final Weeks to Register!

Chemical biology and proteomic strategies are rapidly emerging as cost effective yet powerful preclinical approaches for the discovery and identification of novel drugs and targets. Advances in the development and combination of high-quality chemical tools, bioorthogonal techniques, disease-relevant phenotypic systems, chemoinformatics, proteomics and quantitative mass spectrometry, now provide robust and high-throughput workflows for interrogating drug-target-phenotype relationships. These efforts are poised to significantly enrich preclinical discovery programs and are illuminating a new paradigm for the development of novel drugs modulating novel targets.

Cambridge Healthtech Institute’s Chemical Biology and Proteomics for Target Validation will once again gather an interdisciplinary collection of leaders to discuss these emerging tools and strategies to de-risk novel discovery initiatives  


SusanLindquistFrom Yeast to Human Neurons and Back Again: Powerful Platforms for Chemical Biology and Target Validation

Susan Lindquist, Ph.D., Member, Whitehead Institute for Biomedical Research; Professor of Biology, Massachusetts Institute of Technology; Investigator, Howard Hughes Medical Institute


SeungBumParkFITGE-Based Target Identification for the Connection of Rational Drug Discovery with Phenotypic Screening

Seung Bum Park, Ph.D., Professor, Chemistry, Seoul National University


StevenGygiBioPlex 1.0: An Orfeome-Based, Mass Spectrometry-Driven, Human Protein Interaction Network

Steven P. Gygi, Ph.D., Professor, Cell Biology, Harvard Medical School


BernhardKusterMass Spectrometry-Based Proteomics in Preclinical Drug Discovery

Bernhard Kuster, Ph.D., Professor, Co-Founder and Chair, Proteomics and Bioanalytics, Technische Universität München, OmicScouts GmbH




  • Academic-Industry Strategies to De-Risk Discovery Initiatives
  • Utilization of Chemical Biology and Proteomics for Target Validation
  • Case Studies Targeting Epigenetics, Proteostasis, Protein-Protein Interactions and Novel Biology
  • Phenotypic Screening, Target Deconvolution and MOA of Novel Compounds
  • Novel Synthetic Methods, Chemical Tools and Strategies for Modulation of Biological Processes
  • Interaction with Over 900 Attendees during Networking Breaks and Poster Sessions


  • Arvinas
  • Boston College
  • CeMM
  • Dana-Farber Cancer Institute
  • Duquesne University
  • GlaxoSmithKline
  • H3 Biomedicine
  • Harvard Medical School
  • Howard Hughes Medical Institute
  • Intelligent Pharma
  • Lundbeck Research USA
  • Memorial Sloan Kettering
  • Merck
  • MIT
  • Northwestern University
  • Novartis Institutes for BioMedical Research
  • Pfizer
  • Seoul National University
  • Technische Universitat Munchen
  • The Broad Institute
  • The University of Chicago
  • University of Massachusetts, Amherst
  • University of Toronto
  • Yale University

TVD-Button   CGH-Button 

WPC Colocated Event 

Register Now 




The exhibit hall has sold out the past four years, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2015, contact:

Joseph Vacca
Associate Director, Business Development